# Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

> **NCT05267535** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Neurim Pharmaceuticals Ltd.** · enrollment: 225 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Piromelatine 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05267535
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-12
- **Primary completion:** 2025-06
- **Final completion:** 2025-06
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267535, "Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05267535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*